Aura Biosciences, Inc. Financials
Financial Health Signals
Aura Biosciences, Inc. passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Aura Biosciences, Inc. generates $0.92 in operating cash flow (-$79.8M OCF vs -$86.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
This page shows Aura Biosciences, Inc. (AURA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Aura Biosciences, Inc.'s EBITDA was -$94.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 13.4% from the prior year.
Aura Biosciences, Inc. generated -$81.1M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 25.6% from the prior year.
Aura Biosciences, Inc. reported -$86.9M in net income in fiscal year 2024. This represents a decrease of 13.8% from the prior year.
Aura Biosciences, Inc. earned $-1.75 per diluted share (EPS) in fiscal year 2024. This represents an increase of 9.3% from the prior year.
Aura Biosciences, Inc. held $31.7M in cash against $0 in long-term debt as of fiscal year 2024.
Aura Biosciences, Inc. had 50M shares outstanding in fiscal year 2024. This represents an increase of 1.3% from the prior year.
Aura Biosciences, Inc. invested $73.3M in research and development in fiscal year 2024. This represents an increase of 12.4% from the prior year.
Aura Biosciences, Inc. invested $1.3M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 76.7% from the prior year.
AURA Income Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $22.2M+30.2% | $17.0M | N/A | $15.4M | N/A | $11.3M | N/A | $6.4M |
| SG&A Expenses | $5.7M-7.6% | $6.2M | N/A | $5.1M | N/A | $4.8M | N/A | $2.5M |
| Operating Income | -$27.9M-20.1% | -$23.2M | N/A | -$20.5M | N/A | -$16.1M | N/A | -$8.9M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $26K-39.5% | $43K | N/A | $0 | N/A | N/A | N/A | N/A |
| Net Income | -$26.1M-24.2% | -$21.0M | N/A | -$18.5M | N/A | -$15.9M | N/A | -$8.8M |
| EPS (Diluted) | $-0.40+4.8% | $-0.42 | N/A | $-0.48 | N/A | $-0.54 | N/A | $-28.33 |
AURA Balance Sheet
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $190.0M+4.1% | $182.5M-28.5% | $255.1M+41.9% | $179.8M-19.7% | $223.9M+56.4% | $143.1M-10.5% | $160.0M+76.4% | $90.7M |
| Current Assets | $170.1M+5.9% | $160.6M-30.7% | $231.8M+50.6% | $153.9M-21.8% | $196.7M+69.7% | $115.9M-24.6% | $153.7M+84.2% | $83.5M |
| Cash & Equivalents | $47.6M+50.0% | $31.7M-22.8% | $41.1M-26.1% | $55.6M-54.3% | $121.6M+99.0% | $61.1M-59.0% | $149.1M+82.2% | $81.8M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $33.4M+9.2% | $30.5M+4.5% | $29.2M+4.2% | $28.0M-1.1% | $28.4M+0.9% | $28.1M+264.1% | $7.7M-96.5% | $221.7M |
| Current Liabilities | $18.8M+26.2% | $14.9M+20.7% | $12.4M+13.4% | $10.9M+4.2% | $10.5M+4.9% | $10.0M+35.5% | $7.4M+26.1% | $5.8M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $156.7M+3.1% | $152.0M-32.7% | $225.8M+48.9% | $151.7M-22.4% | $195.6M+70.0% | $115.1M-24.5% | $152.3M+216.3% | -$131.0M |
| Retained Earnings | -$454.9M-21.5% | -$374.2M-30.3% | -$287.3M-8.3% | -$265.2M-25.7% | -$210.9M-8.5% | -$194.3M-27.7% | -$152.1M-8.3% | -$140.5M |
AURA Cash Flow Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$20.1M+15.9% | -$24.0M-37.8% | -$17.4M-12.9% | -$15.4M+14.5% | -$18.0M-67.4% | -$10.8M+11.0% | -$12.1M-39.1% | -$8.7M |
| Capital Expenditures | $45K-84.9% | $299K-5.7% | $317K+252.2% | $90K-74.9% | $358K+468.3% | $63K-92.3% | $819K+42.9% | $573K |
| Free Cash Flow | -$20.2M+16.7% | -$24.3M-37.0% | -$17.7M-14.3% | -$15.5M+15.7% | -$18.4M-69.7% | -$10.8M+16.1% | -$12.9M-39.3% | -$9.3M |
| Investing Cash Flow | -$44.0M-248.2% | $29.7M+133.0% | -$90.1M-516.7% | $21.6M+228.2% | -$16.9M-194.0% | $17.9M+2291.2% | -$819K-42.9% | -$573K |
| Financing Cash Flow | $4.4M+703.5% | $543K-99.4% | $93.0M+5618.6% | $1.6M-98.3% | $95.2M+91437.5% | $104K-99.9% | $80.1M+7281.2% | -$1.1M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
AURA Financial Ratios
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -13.8%-3.5pp | -10.3% | N/A | -10.3% | N/A | -11.1% | N/A | -9.7% |
| Current Ratio | 9.04-1.7 | 10.77-8.0 | 18.76+4.6 | 14.13-4.7 | 18.81+7.2 | 11.63-9.3 | 20.90+6.6 | 14.31 |
| Debt-to-Equity | 0.21+0.0 | 0.20+0.1 | 0.13-0.1 | 0.18+0.0 | 0.14-0.1 | 0.24+0.2 | 0.05+1.7 | -1.69 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Aura Biosciences, Inc. profitable?
No, Aura Biosciences, Inc. (AURA) reported a net income of -$86.9M in fiscal year 2024.
What is Aura Biosciences, Inc.'s earnings per share (EPS)?
Aura Biosciences, Inc. (AURA) reported diluted earnings per share of $-1.75 for fiscal year 2024. This represents a 9.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Aura Biosciences, Inc.'s EBITDA?
Aura Biosciences, Inc. (AURA) had EBITDA of -$94.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Aura Biosciences, Inc.'s free cash flow?
Aura Biosciences, Inc. (AURA) generated -$81.1M in free cash flow during fiscal year 2024. This represents a -25.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Aura Biosciences, Inc.'s operating cash flow?
Aura Biosciences, Inc. (AURA) generated -$79.8M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Aura Biosciences, Inc.'s total assets?
Aura Biosciences, Inc. (AURA) had $182.5M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Aura Biosciences, Inc.'s capital expenditures?
Aura Biosciences, Inc. (AURA) invested $1.3M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Aura Biosciences, Inc. spend on research and development?
Aura Biosciences, Inc. (AURA) invested $73.3M in research and development during fiscal year 2024.
How many shares does Aura Biosciences, Inc. have outstanding?
Aura Biosciences, Inc. (AURA) had 50M shares outstanding as of fiscal year 2024.
What is Aura Biosciences, Inc.'s current ratio?
Aura Biosciences, Inc. (AURA) had a current ratio of 10.77 as of fiscal year 2024, which is generally considered healthy.
What is Aura Biosciences, Inc.'s debt-to-equity ratio?
Aura Biosciences, Inc. (AURA) had a debt-to-equity ratio of 0.20 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Aura Biosciences, Inc.'s return on assets (ROA)?
Aura Biosciences, Inc. (AURA) had a return on assets of -47.6% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Aura Biosciences, Inc.'s cash runway?
Based on fiscal year 2024 data, Aura Biosciences, Inc. (AURA) had $31.7M in cash against an annual operating cash burn of $79.8M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Aura Biosciences, Inc.'s Piotroski F-Score?
Aura Biosciences, Inc. (AURA) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Aura Biosciences, Inc.'s earnings high quality?
Aura Biosciences, Inc. (AURA) has an earnings quality ratio of 0.92x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.